Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Manag Res. 2013 Jun 7;5:91-101. doi: 10.2147/CMAR.S32973. Print 2013.

Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.

Author information

  • 1Department of Medical Oncology, Kinki University, Osakasayama, Japan.

Abstract

The discovery of activating mutations in the epidermal growth-factor receptor (EGFR) gene in 2004 opened a new era of personalized treatment for non-small-cell lung cancer (NSCLC). EGFR mutations are associated with a high sensitivity to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. Treatment with these agents in EGFR-mutant NSCLC patients results in dramatically high response rates and prolonged progression-free survival compared with conventional standard chemotherapy. Subsequently, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK), a novel driver oncogene, has been found in 2007. Crizotinib, the first clinically available ALK tyrosine kinase inhibitor, appeared more effective compared with standard chemotherapy in NSCLC patients harboring EML4-ALK. The identification of EGFR mutations and ALK rearrangement in NSCLC has further accelerated the shift to personalized treatment based on the appropriate patient selection according to detailed molecular genetic characterization. This review summarizes these genetic biomarker-based approaches to NSCLC, which allow the instigation of individualized therapy to provide the desired clinical outcome.

KEYWORDS:

ALK rearrangement; crizotinib; epidermal growth factor receptor; erlotinib; gefitinib; non-small-cell lung cancer

PMID:
23785245
[PubMed]
PMCID:
PMC3682814
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk